CELLTRION INC
BiotechCELLTRION INC is a biotechnology company focused on Immunology, Oncology, Gastroenterology.
CELLTRION INC at a Glance
- Fast trial execution (14 months median completion)
CELLTRION INC's Key Drugs
CELLTRION INC's core commercial portfolio centers on OSENVELT, ZYMFENTRA, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.
CELLTRION INC's Recent FDA Approvals
CELLTRION INC secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
CELLTRION INC's Therapeutic Areas
CELLTRION INC's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CELLTRION INC's Top Competitors
CELLTRION INC's closest competitors by therapeutic-area and drug-target overlap include Novartis, BAUSCH, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CELLTRION INC Pipeline Snapshot
CELLTRION INC has 33 active clinical programs from ClinicalTrials.gov — 26 Phase 3, 0 Phase 2 and 7 Phase 1.
Phase 3 Readout Calendar Pro
5 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OSENVELT leads revenue
- • 2 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 23/30 completed
- • Speed: 14 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2016-04-05
- Latest
- 2026-01-21
- Applications
- 12
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges